Exploring the intricate connection between genetics and cardiovascular health, cardiovascular pharmacogenomics stands at the forefront of medical innovation. This field delves into the genetic factors influencing how individuals respond to cardiovascular drugs, with a primary objective of fine-tuning treatment outcomes and mitigating potential adverse effects. Through a comprehensive analysis of genetic variations impacting drug metabolism, efficacy, and toxicity, cardiovascular pharmacogenomics endeavors to customize medication regimens based on each patient's distinct genetic profile. This personalized approach not only holds the potential to optimize the effectiveness of cardiovascular therapies but also aims to minimize the occurrence of side effects, thereby elevating overall patient outcomes. In an era of advancing genomic understanding, cardiovascular pharmacogenomics emerges as a pivotal player in the ongoing evolution toward precision medicine, paving the way for more nuanced and targeted treatments in the realm of cardiovascular diseases.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt